Skip to main content
Equibles
VVOS logo

VVOS · Vivos Therapeutics, Inc. · Webcasts, Transcripts & Audio

Track VVOS — free

Use VVOS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research VVOS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.15 +0.00 (+1.52%)
Rebalance outlook locked
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“As of June 30, 2026, we had approximately $1.8 million in cash and cash equivalents, which will not be sufficient to fund operations and strategic objectives over the next twelve months from the date of the issuance of these financial statements. Without additional financing, these factors raise substantial doubt regarding the Company's ability to continue as a going concern.”
View the 10-Q filed Aug 14, 2026
Market Cap
$2.83M
Shares
20.12M
Volume · Oct 5 578.8K Avg daily vol (3M) 12.53M

Vivos Therapeutics, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Vivos Therapeutics, Inc. (VVOS), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲32.9% $4.39M −$7.39M '21 Q4 22-03-31 ▲5.7% $3.64M −$5.33M '22 Q1 22-05-16 ▼6.6% $4.25M −$5.43M '22 Q3 22-11-22 ▼10.1% $3.95M −$6.09M '22 Q4 23-03-30 ▲5.8% $3.86M −$1.70M '23 Q1 23-06-08 ▼18.9% $3.40M −$5.53M '23 Q2 23-08-16 ▼17.8% $3.25M −$4.26M '23 Q4 24-03-29 ▼11.4% $3.42M −$3.76M '24 Q1 24-05-15 ▲19.4% $4.05M −$1.93M '24 Q2 24-08-15 ▲16.9% $3.86M −$2.62M '24 Q3 24-11-14 ▲13.9% $3.70M −$2.83M '24 Q4 25-03-31 ▼11.8% $3.02M −$3.86M '25 Q1 25-05-15 ▼5.8% $3.82M −$5.01M '25 Q2 25-08-20 ▲75.7% $6.78M −$5.40M '25 Q3 25-11-19 ▲70.5% $5.14M −$7.68M '26 Q1 26-04-15 LATEST ▲34.9% $5.15M −$5.48M '26 Q2 26-08-14
Earnings call
FY26 · Q2
2026-08-14
Vivos Therapeutics, Inc. (VVOS) Q2 2026 Earnings Call Transcript
Positive tone Sleep Center of Nevada (SCN) acquisition and integration Cardiology group partnerships (Florida, Arizona) Remote patient monitoring on CPAP
Revenue
$5.15M
▲ 34.9% YoY
Diluted EPS
$-0.31
Gross margin
57.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-04-15
Vivos Therapeutics, Inc. (VVOS) Q1 2026 Earnings Call Transcript
Positive tone SCN Acquisition Revenue Growth Cardiologist Collaborations and OSA Market Gross Margin Expansion
Revenue
$5.14M
▲ 70.5% YoY
Diluted EPS
$-0.52
Gross margin
59.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q3
2025-11-19
Vivos Therapeutics, Inc. (VVOS) Q3 2025 Earnings Call Transcript
Confident tone Sleep Center of Nevada (SCN) acquisition integration Provider staffing and ramp-up New medical specialty affiliations (cardiology, neurology)
Revenue
$6.78M
▲ 75.7% YoY
Diluted EPS
$-0.49
Gross margin
58.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-20
Vivos Therapeutics, Inc. (VVOS) Q2 2025 Earnings Call Transcript
Positive tone Sleep Center of Nevada acquisition and integration Revenue decline and financial pressure SO Teams deployment and operations
Revenue
$3.82M
▼ 5.8% YoY
Diluted EPS
$-0.55
Gross margin
55.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-15
Vivos Therapeutics, Inc. (VVOS) Q1 2025 Earnings Call Transcript
Confident tone SCN Acquisition Business Model Pivot to Sleep Centers Financing and Capital Structure
Revenue
$3.02M
▼ 11.8% YoY
Diluted EPS
$-0.45
Gross margin
50.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-31
Vivos Therapeutics, Inc. (VVOS) Q4 2024 Earnings Call
Revenue
$3.70M*
▲ 13.9% YoY
Gross margin
56.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-14
Vivos Therapeutics, Inc. (VVOS) Q3 2024 Earnings Call Transcript
Positive tone CPT codes and reimbursement VIP enrollment decline and deemphasis DME and DSO channel underperformance
Revenue
$3.86M
▲ 16.9% YoY
Diluted EPS
$-0.40
Gross margin
60.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-15
Vivos Therapeutics, Inc. (VVOS) Q2 2024 Earnings Call Transcript
Positive tone VIP enrollment program Operating expenses outlook FDA regulatory clearance
Revenue
$4.05M
▲ 19.4% YoY
Diluted EPS
$-0.60
Gross margin
65.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-15
Vivos Therapeutics, Inc. (VVOS) Q1 2024 Earnings Call Transcript
Positive tone VIP enrollment program Strategic revenue initiative / new partnerships Revenue decline and headwinds
Revenue
$3.42M
▼ 11.4% YoY
Diluted EPS
$-1.63
Gross margin
56.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-29
Vivos Therapeutics, Inc. (VVOS) Q4 2023 Earnings Call Transcript
Positive tone Cost Reduction and Operating Expenses FDA Regulatory Clearances Cash Flow Breakeven and Profitability Path
Revenue
$3.25M*
▼ 17.8% YoY
Gross margin
64.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q2
2023-08-16
Vivos Therapeutics, Inc. (VVOS) Q2 2023 Earnings Call Transcript
Revenue
$3.40M
▼ 18.9% YoY
Diluted EPS
$-4.62
Gross margin
61.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-06-08
Vivos Therapeutics, Inc. (VVOS) Q1 2023 Earnings Call Transcript
Revenue
$3.86M
▲ 5.8% YoY
Diluted EPS
$-1.72
Gross margin
60.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-30
Vivos Therapeutics, Inc. (VVOS) Q4 2022 Earnings Call Transcript
Revenue
$3.95M*
▼ 10.1% YoY
Gross margin
60.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-22
Vivos Therapeutics, Inc. (VVOS) Q3 2022 Earnings Call Transcript
Revenue
$4.25M
▼ 6.6% YoY
Diluted EPS
$-6.40
Gross margin
58.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-16
Vivos Therapeutics, Inc. (VVOS) Q1 2022 Earnings Call Transcript
Revenue
$3.64M
▲ 5.7% YoY
Diluted EPS
$-6.25
Gross margin
70.0%
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-31
Vivos Therapeutics, Inc. (VVOS) Q4 2021 Earnings Call Transcript
Revenue
$4.39M*
▲ 32.9% YoY
Gross margin
70.7%
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-15
Vivos Therapeutics, Inc. (VVOS) Q3 2021 Earnings Call Transcript
Revenue
$4.55M
▲ 38.1% YoY
Gross margin
70.0%
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-12
Vivos Therapeutics, Inc. (VVOS) Q2 2021 Earnings Call Transcript
Revenue
$4.50M
▲ 37.5% YoY
Gross margin
80.6%
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-17
Vivos Therapeutics, Inc. (VVOS) Q1 2021 Earnings Call Transcript
Revenue
$3.45M
▲ 7.9% YoY
Gross margin
78.0%
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-03-25
Vivos Therapeutics, Inc. (VVOS) Q4 2020 Earnings Call
Revenue
$3.31M*
Gross margin
81.3%
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–20 of 20 webcasts
Key facts CIK 1716166 CUSIP 92859E207 13F (30d) 1 filings 1 filers Visit website Investor relations